Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
fMRI Study of Mevidalen in Healthy Subjects
NCT04258826Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Lewy body dementia (LBD) and Parkinson's disease dementia (PDD) comparing Mevidalen with Placebo (2 arms). Primary endpoint: Change from Baseline in Intrinsic Functional Connectivity Among Resting-State Networks of the Brain at Day 28. Started Jan 2021; status: completed.
02
Drugs
mevidalen
03
Conditions
Lewy body dementia (LBD)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT04258826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258826.